Less-Frequent Zoledronic Acid Treatment Effective at Preventing Bone Metastasis Complications

In a clinical trial involving patients with metastatic cancer, administration of zoledronic acid every 12 weeks was as effective at preventing skeletal-related events caused by bone metastases as administration every 4 weeks.

Cancer Currents: An NCI Cancer Research Blog